Startup profile for Remedy Robotics: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Remedy Robotics funding, valuation and investors

Developer of the investigational N1 robot for image-guided, remotely operable endovascular procedures.

Verified company research · funding, investors and latest developments

Keep track of Remedy Robotics

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series B

$62M · November 16, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$62M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series b · San Francisco, California, United States

Investors in latest funding

Lead: DCVC

Other: UC Investments , Skip Capital , Hostplus , Build Collective , Blackbird , Divergent Capital , KdT Ventures

Sources: latest funding · prnewswire.com Last verified: 2026-11-16

Overview

Remedy Robotics develops the N1 image-guided robotic platform intended to let specialist physicians conduct complete minimally invasive catheter procedures at a hospital, from another site, or with future supervised autonomous assistance. Its software uses preoperative imaging, case simulation and 3D-to-2D registration to support catheter navigation.

The company reported first-in-human procedures in Toronto in 2024 and remote human procedures in 2025. The N1 is investigational, not FDA-approved or available for commercial sale; safety, effectiveness, pricing and procurement terms are not established.

Why Remedy Robotics is interesting

Its November 16, 2026 $62M Series B, led by DCVC, is intended to fund a pivotal trial and FDA review rather than scale sales of an approved product. Remote neurovascular procedures have been reported in small first-in-human studies, but no approved commercial device or validated economic outcome has been established.

Product & use cases

Representative clinician workflow (illustrative, not a hands-on test): (1) hospital identifies a patient requiring specialist neurovascular intervention and acquires the necessary imaging; (2) trained physician reviews the images and proposed plan; (3) N1 software analyzes preoperative imaging and offers case simulation and image registration; (4) the physician remotely or locally controls robotic tools through an operator console, with imaging feedback; (5) clinician evaluates the procedural result and provides standard post-procedure monitoring. Remedy's own website describes 2024 first-in-human and 2025 remote demonstrations. Such studies do not prove general clinical safety, commercial readiness or unsupervised autonomy.

  • Potential inter-hospital remote thrombectomy for regions without on-site specialists; proposed future use, not currently offered clinical service.
  • Physician-operated endovascular catheter procedures with robotic precision in controlled research settings.
  • Pre-procedure imaging interpretation and procedural simulation for specialists.

Key facts

  • $62M Series B announced Nov 16, 2026, led by DCVC; legal settlement date and valuation undisclosed.
  • New investors UC Investments, Skip Capital and Hostplus; returning Build Collective, Blackbird, Divergent Capital and KdT Ventures.
  • Company reports relationships with over 100 hospitals, NOT 100 commercial deployments or proven outcomes.
  • N1 remains an investigational device; FDA clearance or approval has not been established.

Funding history (newest first)

Series B

2026-11-16 $62M
  • DCVC (lead)
  • UC Investments (participant)
  • Skip Capital (participant)
  • Hostplus (participant)
  • Build Collective (participant)
  • Blackbird (participant)
  • Divergent Capital (participant)
  • KdT Ventures (participant)

Source: Read source · prnewswire.com

Competitive landscape

Edge: Claimed differentiation is end-to-end robotic catheter procedures with teleoperation and machine-learning visualization. The extent of clinical benefit versus standard catheterization and other robotics has not been established by independently verified comparative studies.

Primary comparison is to manual specialist-delivered intervention and existing robot-assisted vascular systems. Key adoption gates: rigorous pivotal trial results, FDA authorization for specific indications, physician training, cath-lab infrastructure, connectivity resiliency, workflow handoff, reimbursement and purchase/service economics. Never label its remote cases proof of better outcomes or its hospital network as paying customers.

  • Conventional manual endovascular thrombectomy incumbent

    Existing clinical standard delivered by specialist neurointerventional teams; no robot purchase but requires specialized local staff.

  • Corindus/Siemens Healthineers CorPath adjacent

    Established robotic vascular intervention platform; application scope and regulatory indications differ and require careful procedure-level comparison.

  • Microbot Medical LIBERTY adjacent

    Robotic endovascular platform with a different technology/indication path; no evidence that users can interchange them directly.

Notable stories

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Remedy Robotics

Practical answers founders, operators, and investors typically search for.

No. Its issuer states that N1 is investigational, not available for sale or clinical use; pivotal trials and FDA review are planned.
No valuation or prior cumulative financing amount was disclosed in the November 16 announcement.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.